Longeveron Inc. (NASDAQ:LGVN – Get Free Report) was the target of a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 157,139 shares, a growth of 114.7% from the October 15th total of 73,177 shares. Currently, 5.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 72,097 shares, the days-to-cover ratio is presently 2.2 days.
Institutional Trading of Longeveron
An institutional investor recently bought a new stake in Longeveron stock. ADAR1 Capital Management LLC acquired a new stake in Longeveron Inc. (NASDAQ:LGVN – Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned approximately 0.86% of Longeveron at the end of the most recent quarter. Hedge funds and other institutional investors own 10.01% of the company’s stock.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the company. Weiss Ratings lowered Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. Wall Street Zen cut shares of Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $80.00.
Read Our Latest Stock Analysis on Longeveron
Longeveron Trading Down 11.6%
LGVN stock traded down $0.29 during mid-day trading on Monday, reaching $2.20. 25,882 shares of the stock traded hands, compared to its average volume of 205,697. Longeveron has a 52-week low of $1.31 and a 52-week high of $12.30. The company has a market cap of $7.02 million, a P/E ratio of -0.28 and a beta of -0.09. The stock’s fifty day moving average is $2.92 and its 200-day moving average is $6.44.
Longeveron (NASDAQ:LGVN – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($1.91) earnings per share for the quarter, missing the consensus estimate of ($1.70) by ($0.21). Longeveron had a negative net margin of 1,921.72% and a negative return on equity of 243.26%. The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.80 million. Equities research analysts expect that Longeveron will post -7.20 earnings per share for the current year.
About Longeveron
Longeveron Inc. is a clinical-stage biotechnology company based in Miami, Florida, developing cell-based therapies for serious and age-related conditions. Its research focuses on medicinal signaling cells, a type of adult stem cell that may influence the body’s repair and immune responses. The company’s lead product candidate, Lomecel-B, is an investigational therapy made from donated bone marrow cells. Longeveron has studied it for conditions including hypoplastic left heart syndrome, Alzheimer’s disease and aging-related frailty.
Further Reading
- Five stocks we like better than Longeveron
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.
